The Immunomodulators Market Outlook to 2016
Business Insights
August 5, 2011 159 Pages - SKU: RET6489212
|
|
Introduction
The report provides comprehensive coverage of the global immunomodulators market, incorporating disease overviews, and epidemiological analyses. This report captures and assesses leading marketed products, R&D pipelines, sales forecast and key market players. It also highlights key trends that will influence sales through 2016.
Features and benefits- Assess the patient potential and treatment trends of the major immune related diseases globally.
- Analyse the dynamics of the immunomodulators market and understand the impact of key R&D events, market trends, and issues.
- Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers.
- Identify the leading pipeline products in the forecast sales to 2016.
- Develop strategies for success in the future CNS market.
Highlights
TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, with the top three products: Remicade, Humira and Enbrel accounting for 40.1% of the market in 2010.
Novartis’ orally formulated Gilenya for multiple sclerosis will gain extensive market share reaching sales of $2.3bn by 2016. Copaxone and Avonex sales will decline strongly to 2016.
GSK and Human Genome Sciences’ Benlysta was the first product to be approved for the treatment of systemic lupus erythematous in the past 30 years, a key step in the disease treatment. Benlysta will reach sales of $401m in 2016.
Your key questions answered- What are the current growth drivers in the global immunomodulator market?
- What are the new therapeutic approaches in the immunomodulators market and which of these offer significant potential in the future?
- What is the forecast commercial potential of the most promising compounds in clinical development?
- Who are the leading players in each indication in the immunomodulators market, and what are their strategies?
- How will the launch of late stage pipeline products and patent expires impact the market to 2016?
|
- Executive Summary
- Introduction
- Multiple sclerosis
- Rheumatoid arthritis, psoriasis and inflammatory bowel disease
- Systemic lupus erythematosus
- Organ transplantation
- About the author
- Disclaimer
- Introduction
- Summary
- Introduction
- Components of the immune system
- Components of acquired immunity
- The complement system
- Trends
- Unmet need in rheumatoid arthritis
- Unmet needs in Crohn’s disease
- Unmet need in multiple sclerosis
- EU guidelines for monoclonal antibodies biosimilars
- Ethical concerns over transplantation
- Market size
- Global market size
- Geographic segmentation
- Multiple sclerosis
- Summary
- Introduction
- Disease overview
- Definition
- Clinical manifestation of multiple sclerosis
- Types of multiple sclerosis
- Etiology
- Pathophysiology
- Diagnosis
- Treatment
- Economic burden of disease
- Epidemiology
- Forecast epidemiology
- Current marketed therapies
- Copaxone
- Avonex
- Rebif
- Betaseron
- Tysabri
- Key players
- Biogen IDEC
- Bayer
- Teva
- Merck Serono
- Novartis
- Key pipeline products
- BG-12/Panaclar - Biogen IDEC
- Alemtuzumab - Genzyme
- Teriflunomide - Sanofi
- Laquinimod - Teva
- Daclizumab
- Sales forecast
- Rheumatoid arthritis, psoriasis and inflammatory bowel disease
- Summary
- Introduction
- Rheumatoid arthritis
- Pathophysiology
- Diagnosis
- Treatment
- Epidemiology
- Forecast epidemiology
- Inflammatory bowel disease
- Pathophysiology
- Etiology
- Diagnosis
- Epidemiology
- Forecast epidemiology
- Psoriasis
- Overview
- Pathogenesis
- Symptoms
- Treatment
- Assessment of the response to biologicals
- Epidemiology
- Forecast epidemiology
- Current marketed therapies
- Remicade
- Simponi
- Enbrel
- Humira
- Cimzia
- Non-anti-TNF biologics for rheumatoid arthritis
- Rituxan/Mabthera
- Orencia
- Actemra
- Key players
- Pfizer
- Abbott
- Johnson & Johnson
- Key pipeline products
- Fostamatinib disodium - AstraZeneca
- Tofacitinib - Pfizer
- Sales forecast
- Systemic lupus erythematosus
- Summary
- Introduction
- Disease overview
- Pathophysiology
- Symptoms
- Diagnosis
- Treatment
- Epidemiology
- Forecast epidemiology
- Current marketed therapies
- Benlysta
- NSAIDs
- Antimalarials
- Glucocorticoids
- Cytotoxic/immunosuppressive agents
- Key pipeline products
- Lupuzor - Cephalon
- Epratuzumab - UCB
- Sales forecast
- Organ transplantation
- Summary
- Introduction
- Disease overview
- Immunobiology of rejection
- Genetic factors
- Mechanisms of rejection
- Apoptosis
- Stages of rejection
- Episode of acute rejection
- Epidemiology
- Forecast number of transplants
- Current marketed therapies
- Cellcept
- Prograf
- Key players
- Roche
- Key pipeline products
- Nulojix - BMS
- Voclosporin - Isotechnika
- Sales forecast
- Appendix
- Scope
- Methodology
- Market size methodology
- Epidemiology
- Market forecast
- Abbreviations
- Bibliography/references
Share this report
Other tasks Related Markets Prescription Drugs Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
